MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 525637 | Name: MK-0608
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

MK 0608 is an anti-viral agent against Hepatitis C Virus (HCV). It has been shown to inhibit viral RNA replication in the subgenomic HCV genotype 1b replicon, with a 50% effective concentration (EC50) of 0.3 μM (EC90 = 1.3 μM). To determine efficacy in vivo, MK-0608 was administered to HCV-infected chimpanzees, resulting in dose- and time-dependent decreases in plasma viral loads. In separate experiments, chimpanzees dosed for 7 days with MK-0608 at 0.2 and 2 mg per kg of body weight per day by intravenous administration experienced average reductions in viral load of 1.0 and >5 log10 IU/ml, respectively.

Chemical Structure

MK-0608
MK-0608
CAS#443642-29-3

Theoretical Analysis

MedKoo Cat#: 525637

Name: MK-0608

CAS#: 443642-29-3

Chemical Formula: C12H16N4O4

Exact Mass: 280.1172

Molecular Weight: 280.28

Elemental Analysis: C, 51.42; H, 5.75; N, 19.99; O, 22.83

Price and Availability

Size Price Availability Quantity
5mg USD 350.00 2 Weeks
25mg USD 750.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
MK0608; MK-0608; MK 0608; MK608; MK-608; MK 608; 7-deaza-2’-C-methyladenosine, 7-DMA.
IUPAC/Chemical Name
(2R,3R,4R,5R)-2-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5-(hydroxymethyl)-3-methyltetrahydrofuran-3,4-diol
InChi Key
IRZRJANZDIOOIF-GAJNKVMBSA-N
InChi Code
InChI=1S/C12H16N4O4/c1-12(19)8(18)7(4-17)20-11(12)16-3-2-6-9(13)14-5-15-10(6)16/h2-3,5,7-8,11,17-19H,4H2,1H3,(H2,13,14,15)/t7-,8-,11-,12-/m1/s1
SMILES Code
NC1=C2C(N([C@H]3[C@]([C@@H]([C@@H](CO)O3)O)(C)O)C=C2)=NC=N1
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Certificate of Analysis
View CoA: current batch, Lot#S9C10T29
Safety Data Sheet (SDS)
View Safety Data Sheet (SDS)
Instruction
View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 280.28 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Eyer L, Kondo H, Zouharova D, Hirano M, Valdés JJ, Muto M, Kastl T, Kobayashi S, Haviernik J, Igarashi M, Kariwa H, Vaculovicova M, Cerny J, Kizek R, Kröger A, Lienenklaus S, Dejmek M, Nencka R, Palus M, Salat J, De Clercq E, Yoshii K, Ruzek D. Escape of tick-borne flavivirus from 2' -C-methylated nucleoside antivirals is mediated by a single conservative mutation in NS5 that has a dramatic effect on viral fitness. J Virol. 2017 Aug 16. pii: JVI.01028-17. doi: 10.1128/JVI.01028-17. [Epub ahead of print] PubMed PMID: 28814513; PubMed Central PMCID: PMC5640847. 2: Lanko K, Eggermont K, Patel A, Kaptein S, Delang L, Verfaillie CM, Neyts J. Replication of the Zika virus in different iPSC-derived neuronal cells and implications to assess efficacy of antivirals. Antiviral Res. 2017 Sep;145:82-86. doi: 10.1016/j.antiviral.2017.07.010. Epub 2017 Jul 20. PubMed PMID: 28736077. 3: Elfiky AA, Mahdy SM, Elshemey WM. Quantitative structure-activity relationship and molecular docking revealed a potency of anti-hepatitis C virus drugs against human corona viruses. J Med Virol. 2017 Jun;89(6):1040-1047. doi: 10.1002/jmv.24736. Epub 2017 Feb 16. PubMed PMID: 27864902. 4: Elfiky AA. Zika viral polymerase inhibition using anti-HCV drugs both in market and under clinical trials. J Med Virol. 2016 Dec;88(12):2044-2051. doi: 10.1002/jmv.24678. Epub 2016 Sep 20. PubMed PMID: 27604059. 5: Zmurko J, Marques RE, Schols D, Verbeken E, Kaptein SJ, Neyts J. The Viral Polymerase Inhibitor 7-Deaza-2'-C-Methyladenosine Is a Potent Inhibitor of In Vitro Zika Virus Replication and Delays Disease Progression in a Robust Mouse Infection Model. PLoS Negl Trop Dis. 2016 May 10;10(5):e0004695. doi: 10.1371/journal.pntd.0004695. eCollection 2016 May. PubMed PMID: 27163257; PubMed Central PMCID: PMC4862633. 6: Eyer L, Valdés JJ, Gil VA, Nencka R, Hřebabecký H, Šála M, Salát J, Černý J, Palus M, De Clercq E, Růžek D. Nucleoside inhibitors of tick-borne encephalitis virus. Antimicrob Agents Chemother. 2015 Sep;59(9):5483-93. doi: 10.1128/AAC.00807-15. Epub 2015 Jun 29. PubMed PMID: 26124166; PubMed Central PMCID: PMC4538560. 7: Mello C, Aguayo E, Rodriguez M, Lee G, Jordan R, Cihlar T, Birkus G. Multiple classes of antiviral agents exhibit in vitro activity against human rhinovirus type C. Antimicrob Agents Chemother. 2014;58(3):1546-55. doi: 10.1128/AAC.01746-13. Epub 2013 Dec 23. PubMed PMID: 24366736; PubMed Central PMCID: PMC3957863. 8: Ohara E, Hiraga N, Imamura M, Iwao E, Kamiya N, Yamada I, Kono T, Onishi M, Hirata D, Mitsui F, Kawaoka T, Tsuge M, Takahashi S, Abe H, Hayes CN, Ochi H, Tateno C, Yoshizato K, Tanaka S, Chayama K. Elimination of hepatitis C virus by short term NS3-4A and NS5B inhibitor combination therapy in human hepatocyte chimeric mice. J Hepatol. 2011 May;54(5):872-8. doi: 10.1016/j.jhep.2010.08.033. Epub 2010 Oct 26. PubMed PMID: 21145818. 9: Olsen DB, Davies ME, Handt L, Koeplinger K, Zhang NR, Ludmerer SW, Graham D, Liverton N, MacCoss M, Hazuda D, Carroll SS. Sustained viral response in a hepatitis C virus-infected chimpanzee via a combination of direct-acting antiviral agents. Antimicrob Agents Chemother. 2011 Feb;55(2):937-9. doi: 10.1128/AAC.00990-10. Epub 2010 Nov 29. PubMed PMID: 21115793; PubMed Central PMCID: PMC3028818. 10: Carroll SS, Ludmerer S, Handt L, Koeplinger K, Zhang NR, Graham D, Davies ME, MacCoss M, Hazuda D, Olsen DB. Robust antiviral efficacy upon administration of a nucleoside analog to hepatitis C virus-infected chimpanzees. Antimicrob Agents Chemother. 2009 Mar;53(3):926-34. doi: 10.1128/AAC.01032-08. Epub 2008 Dec 15. PubMed PMID: 19075052; PubMed Central PMCID: PMC2650549. 11: Schul W, Liu W, Xu HY, Flamand M, Vasudevan SG. A dengue fever viremia model in mice shows reduction in viral replication and suppression of the inflammatory response after treatment with antiviral drugs. J Infect Dis. 2007 Mar 1;195(5):665-74. Epub 2007 Jan 23. PubMed PMID: 17262707.